Sudeep Pharma (SUDEEPPHRM) investor relations material

Executive summary

• Q1 FY27 revenue grew 27% year-over-year to Rs. 158.3 Cr (Rs. 15,827.05 lakhs), driven by strong performance across Pharma, Food & Nutrition, and Specialty Ingredients segments despite global headwinds.

• Operational excellence, improved manufacturing efficiencies, and disciplined cost management supported resilient results.

• Greenfield expansion and Sudeep Advanced Materials (SAM) projects are progressing on schedule, with Phase 1 of SAM set for commissioning by March 2027.

• Integration of NSS in Europe is advancing, aiming to enhance efficiencies and profitability; NSS acquisition completed and became a step-down subsidiary in May 2025.

• Board strengthened with the appointment of an experienced Independent Director.

Financial highlights

• Q1 FY27 revenue from operations: Rs. 158.3 Cr, up 27% year-over-year; total income at Rs. 16,371.59 lakhs.

• EBITDA for Q1 FY27: Rs. 54.9 Cr, up 25% year-over-year; EBITDA margin at 34.7%.

• PAT for Q1 FY27: Rs. 40.6 Cr, up 30% year-over-year; PAT margin at 25.6%.

• EPS for Q1 FY27: 3.59 (not annualized), up from 2.84 in the prior year.

• FY26 revenue: Rs. 642.3 Cr; EBITDA: Rs. 221.9 Cr (34.6% margin); PAT: Rs. 174.3 Cr (27.1% margin).

Outlook and guidance

• Greenfield expansion on track to enhance manufacturing capacity and product portfolio.

• SAM Phase 1 commissioning by March 2027; Phase 2 planning initiated due to strong customer engagement.

• Continued focus on disciplined working capital management and capital efficiency.

• Unutilized IPO proceeds of Rs. 7,545.63 lakhs remain, earmarked for capital expenditure and general corporate purposes.

• Positioned for sustainable long-term growth through innovation and capacity investments.